CRISPR/dCas9 blocks TGF-β2-induced mouse double minute 2 (MDM2) expression by targeting its second promoter, without affecting the basal expression. Epithelial to mesenchymal transition is blocked by MDM2 suppression in retinal pigment epithelial cells. In this way, CRIPSR/dCas9 is a promising novel therapy for proliferative vitreoretinopathy without interfering basal gene function.
- Bing Liu
- Jingyuan Song
- Hetian Lei